Prothena Corporation plc has released a presentation detailing its focus on delivering life-saving therapies for diseases caused by protein dysregulation, including Alzheimer's disease, Parkinson's disease, and Transthyretin amyloidosis. The presentation highlights the company's multiple ongoing clinical programs, including two partnered Phase 3 programs, one partnered Phase 2 program, one partnered Phase 1 program, and one wholly-owned Phase 1 program. Prothena has established strong collaborations with major companies such as Bristol Myers Squibb, Novo Nordisk, and Roche. The presentation also emphasizes Prothena's expertise in epitope mapping and disease-driven antibody engineering, aiming to optimize therapeutic outcomes for patients. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.